Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2021 09:05 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
November 29, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
November 08, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit

Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
November 03, 2021 10:00 ET | Source: Lynx Biosciences, Inc.

Lynx Biosciences Closes Series Seed Equity Round Led by Checkmate Capital Group

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lynx Biosciences, Inc. ("LynxBio®"), a San Diego-based biotechnology company, today announced the successful closing of its Series Seed Preferred Stock...
October 06, 2021 11:10 ET | Source: Medlab Clinical Ltd

NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE

SYDNEY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX.MDC) is pleased to announce NanoCelle® the company’s proprietary delivery platform has been issued a “Notice of Allowance” by the...
August 10, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285

Patent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a...
March 29, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
March 04, 2021 08:00 ET | Source: F-star Therapeutics, Inc.

F-star Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
February 23, 2021 08:00 ET | Source: Celsion CORP

Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
January 22, 2021 08:40 ET | Source: Celsion CORP

CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...